TD Asset Management’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

TD Asset Management’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-213,896	Closed	-$575K	–	1468
2023 Q3	$575K	Buy	213,896 +106,948	+100%	+$419K	﹤0.01%	1242
2023 Q2	$998K	Hold	106,948	–	–	﹤0.01%	1131
2023 Q1	$950K	Hold	106,948	–	–	﹤0.01%	1144
2022 Q4	$533K	Hold	106,948	–	–	﹤0.01%	1277
2022 Q3	$652K	Hold	106,948	–	–	﹤0.01%	1250
2022 Q2	$591K	Buy	106,948 +39,815	+59%	+$329K	﹤0.01%	1265
2022 Q1	$774K	Buy	67,133 +10,931	+19%	+$117K	﹤0.01%	1276
2021 Q4	$713K	Buy	+56,202	New	+$849K	﹤0.01%	1338

Other funds holding THRX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

TD Asset Management's THRX Position: Q4 2023 in Review

TD Asset Management sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q4 2023, closing a stake of 213,896 shares — an estimated $575K sold.

TD Asset Management first reported a position in THRX in Q4 2021 and held it in 8 quarters. The position peaked at $998K in Q2 2023. 70 funds tracked by Wall St. Rank hold THRX as of Q4 2023.

TD Asset Management reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
TD Asset Management sold 213,896 Theseus Pharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $575K.
TD Asset Management first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 8 quarters.
TD Asset Management's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $998K in Q2 2023.
70 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on TD Asset Management's 13F filing for Q4 2023, filed 12 Feb 2024.